ICU | Sepsis | Cardiac arrest | Trauma | |
---|---|---|---|---|
Number of patients | 1978 | 632 (32%) | 190 (9.6%) | 157 (7.9%) |
Women (%) | 39 | 40 | 27 | 23 |
ICU length-of-stay (days) | 1.7 (0.8–3.8) | 2.5 (1.1–5.5) | 2.4 (0.97–4.3) | 1.8 (0.93–4.1) |
ICU mortality (%) | 11 | 14 | 34 | 4.5 |
30-day mortality (%) | 22 | 28 | 54 | 12 |
SAPS-3 score | 59 (47–71) | 66 (57–77) | 76 (66–87) | 48 (39–59) |
Day-one SOFA score | 7 (4–10) | 8 (6–11) | 10 (8–13) | 5 (2–7) |
Day-two SOFA score (n = 995) | 8 (5–10) | 8 (6–11) | 10 (8–12) | 6 (4–9) |
CRRT during ICU stay (%) | 9.2 | 15 | 7.4 | 0.6 |
Box I | ||||
Age (years) | 66 (54–74) | 69 (61–76) | 68 (60–76) | 55 (33–70) |
Comorbidities | ||||
- Cancer therapy (%) | 4.6 | 6.3 | 4.2 | 0.6 |
- Chronic heart failure (%) | 5.5 | 7.0 | 10 | 1.3 |
- Haematological cancer (%) | 2.6 | 5.2 | 1.0 | 0 |
- Liver cirrhosis (%) | 1.1 | 1.6 | 0 | 0 |
- Cancer (%) | 10.4 | 10.4 | 7.9 | 1.3 |
Vasoactive drugs before ICU (%) | 44 | 47 | 64 | 21 |
Box II | ||||
Surgical status at ICU admission | ||||
- No surgery (%) | 74 | 85 | 94 | 83 |
Box III | ||||
GCS | 13 (10–15) | 13 (10–15) | 3 (3–8) | 10 (6–15) |
Total bilirubin (μmol/L) | 9 (6–15) | 10 (7–19) | 8 (5–12) | 8 (5–12) |
Max. temperature (∘C) | 37.0 (36.3–37.6) | 37.3 (36.5–38.1) | 36.0 (35.5–36.8) | 37.0 (36.0–37.5) |
Max. creatinine (μmol/L) | 93 (70–145) | 119 (79–205) | 112 (87–149) | 87 (74–111) |
Max. heart rate (bpm) | 100 (80–118) | 107 (90–122) | 98 (80–115) | 90 (80–110) |
Max. leukocyte count (×109/L) | 13 (8.8–18) | 13 (8.4–19) | 16 (12–21) | 14 (11–19) |
Min. pH | 7.34 (7.24–7.41) | 7.32 (7.20–7.40) | 7.19 (7.04–7.3) | 7.34 (7.29–7.40) |
Min. platelet count (×109/L) | 221 (161–286) | 218 (147–304) | 222 (165–270) | 212 (171–261) |
Min. systolic blood pressure (mmHg) | 100 (80–120) | 91 (75–115) | 85 (68–109) | 104 (90–130) |
Oxygenation | ||||
- Respiratory support (%) | 58 | 59 | 86 | 53 |
- FiO2 (%) | 50 (40–70) | 60 (40–80) | 60 (50–80) | 45 (40–57) |
- PaO2 (kPa) | 13 (9.8–18) | 11 (9.0–15) | 13 (11–22) | 16 (11–24) |
Other | ||||
cDPP3 (ng/mL) | 19 (13–33) | 19 (13–31) | 44 (28–69) | 22 (14–38) |